UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
10.08
-0.63 (-5.88%)
At close: Feb 21, 2025, 4:00 PM
10.27
+0.19 (1.86%)
After-hours: Feb 21, 2025, 5:54 PM EST
UroGen Pharma Employees
As of December 31, 2023, UroGen Pharma had 201 total employees, including 198 full-time and 3 part-time employees. The number of employees increased by 1 or 0.50% compared to the previous year.
Employees
201
Change (1Y)
1
Growth (1Y)
0.50%
Revenue / Employee
$444,592
Profits / Employee
-$574,020
Market Cap
425.37M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
URGN News
- 2 days ago - UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations - Business Wire
- 8 days ago - UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 - Business Wire
- 10 days ago - Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology - Business Wire
- 22 days ago - UroGen: Upcoming PDUFA, Some Concerns Remain - Seeking Alpha
- 23 days ago - UroGen Pharma to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) - Business Wire
- 5 weeks ago - ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Business Wire
- 2 months ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire